Tirzepatide Safe and Effective in Adolescents With Obesity
NATIONAL HARBOR, Md. — Adolescents with obesity and at least one obesity-related complication treated with tirzepatide showed significant reductions in BMI, with safety and efficacy consistent with results observed in previous trials involving adults, according to results from the phase 3 SURMOUNT-ADOLESCENTS trial. “This is the first large, randomized trial of tirzepatide in adolescents who have obesity without type 2 diabetes, and the size of the effect is remarkable,” co-author Gitanjali Srivastava, MD, of Department of Pediatrics, Vanderbilt Health, and co-director of the Vanderbilt Weight Loss Center in Nashville, Tennessee, told Medscape Medical News . “After 72 weeks, more than half of participants no longer met the BMI criteria for obesity,” she said. The trial results were presented at Obesity Week 2026 and published simultaneously in JAMA . Big Reduction in BMI A total of 160 adolescents with obesity, aged 12-18 years, were enrolled in the double-blind study at 31 international centers. The patients had a mean age of 14.6 years, and about 62% were female. Their mean baseline body weight was 109.7 kg, with mean BMI of 38.6, indicative of severe obesity. One patient in the placebo group had type 2 diabetes (T2D), and one in the tirzepatide group had prediabetes. Participants were randomly assigned to once weekly, subcutaneous tirzepatide escalated to a maximum tolerated dose of 5, 10, or 15 mg (n = 109) or to placebo (n = 51), along with a healthy lifestyle intervention for 72 weeks. The tirzepatide group showed an 18.5% reduction in BMI compared with a 0.5% increase in BMI in the placebo group receiving a healthy lifestyle intervention alone (estimated treatment difference, -19%; P < .001). Overall, there were 10 secondary endpoints, and all showed significant improvements in the tirzepatide group compared to the placebo group. Nearly 80% of those in the tirzepatide group achieved a BMI reduction of at least 5%, compared with just 28.5% in the placebo group ( P < .001). And nearly half of those in the tirzepatide group (48.1%) achieved at least a 20% reduction in BMI, compared with 7.9% in the placebo group. As of the 72-week cutoff, 54% of the tirzepatide-treated group had a BMI below the 95th percentile obesity threshold. Greater improvements with tirzepatide were also observed in systolic and diastolic blood pressure as well as lipids and triglycerides, with additional improvements in glycemic measures and A1c and self-esteem domain scores. “The current findings show a magnitude of weight reduction in adolescents consistent with results from the SURMOUNT-1 study in adults [approximately 20% body weight reduction with tirzepatide 10 mg and 15 mg],” the authors noted in the study. The results also add to previous evidence from the SURPASS-PEDS trial involving children with youth-onset T2D, in which tirzepatide (5 mg and 10 mg) was associated with both improved glycemic management and reduced BMI. Adverse Events (AEs) One or more AEs occurred in 95.4% of those in the tirzepatide group and 82.4% of the placebo group. They were described as mostly mild to moderate in severity, with gastrointestinal events being the most common AEs with tirzepatide (81.5%). Symptoms including nausea, vomiting, and diarrhea were more common during the dose escalation phase, and 22.2% of patients in the tirzepatide group required antiemetic medication vs 3.9% in the placebo group. Overall, 86 participants treated with tirzepatide completed treatment at week 72, including 61.6% receiving 15 mg, 15.1% receiving 10 mg, and 23.3% receiving 5 mg. Depression, Suicidal Ideation Rates Low Reports of depression or suicidal ideation occurred in five (4.6%) tirzepatide-treated patients vs one (2%) placebo participant, with none of the cases considered serious, said co-author Claudia Fox, MD, MPH, co-director of the Center for Pediatric Obesity Medicine at the University of Minnesota in Minneapolis, who presented the safety outcomes at the meeting. In addition, there were no differences between the groups in reports of worsening depressive symptoms to moderate or greater severity. Fox noted previous concerns of the potential effects of tirzepatide on mental health but put the numbers into context. “The prevalence of depression and suicidal ideation in adolescence with obesity is quite high, anywhere from 20% to 25%,” she explained. “So in that context, the numbers that we saw in this trial were quite low.” She added that postmarketing analyses looking at the risks for depression and suicidality among people taking GLP-1 receptor agonists (RAs) have found no association between the two, resulting the removal of the warning from drug labels. “Nevertheless, adolescence does represent a very vulnerable time, and these are individuals who do need very close monitoring of their mental health,” said Fox. In the study, tirzepatide treatment was associated with improvements in the Impact of Weight on Quality of Life-Kids score, driven primarily by improvement in the Physical Comfort and Body Esteem domain scores. “Teens reported better physical comfort and body esteem, and for this age group, those are clinical outcomes, not extras,” Srivastava said. Screen for Eating Disorders With tirzepatide’s reputation as the powerhouse of GLP-1s in terms of weight reduction, and eating disorders an ongoing concern particularly among adolescents, Srivastava pointed out that screening matters. “Every adolescent being considered for obesity medication should be screened for disordered eating before starting and monitored during treatment,” she said. Regarding the suggestion of initiating therapy on a less potent GLP-1, Srivastava noted that there is no evidence suggesting that adolescents need to “fail” semaglutide or liraglutide before trying tirzepatide, and step therapy is not necessarily recommended. “We don’t make adults with hypertension fail a weaker drug before giving them the effective one,” she said. “The choice should depend on the degree of obesity, comorbidities, tolerability, and access.” Broader evidence regarding pediatric obesity treatment has indicated that “structured, medically supervised weight management does not increase eating disorder risk, and it often reduces binge-eating behavior,” she explained. Dosing in Adolescents Srivastava added that “more weight loss” in a teen with severe obesity should refer to getting closer to a healthy BMI, “not dropping below one.” “Where clinical judgment comes in is dose,” she added. “If a teen reaches a healthy weight trajectory, we don’t need to keep escalating. These medications should be dosed to the patient, not to the maximum.” While there is not necessarily a separate protocol for adolescent dosing, clinicians should consider “starting low, going slow when needed, and paying attention to whether the teen is eating and drinking enough,” Srivastava recommended. This is more important than following a rigid schedule, she added. Long-Term Treatment? Questions surround the prospect of long-term treatment with tirzepatide starting in adolescence. Though also an issue in adults, due to the known reversal of benefits when the drugs are discontinued, the concerns are greater with still-developing bodies. “We don’t yet have long-term data on [tirzepatide’s] effects on growth, bone mineral density, pubertal development, or mental health,” said Srivastava. However, “obesity is a chronic disease, and adult data show weight comes back when these medications are stopped,” she noted. “We should expect the same in teens and plan for long-term treatment.” Other GLP-1 RAs including liraglutide and semaglutide have been approved by the FDA for the long-term treatment of obesity in adolescents. And while tirzepatide is approved for adults with obesity but not T2D, and for children aged 10 years or older with T2D, the drug is not approved for adolescents without diabetes. The current findings, however, offer encouraging evidence for that purpose, Srivastava said. “Until now, our adolescent tirzepatide data came from teens with T2D and from small case series,” she noted. “This trial gives us placebo-controlled evidence in the population that we actually treat the most.” The trial was sponsored by Eli Lilly. Srivastava reported serving as an advisor for Eli Lilly, Novo Nordisk, Rhythm, Madrigal, and Quest Diagnostics. Fox reported serving as a contracted researcher for Novo Nordisk, with compensation paid directly to her employer, University of Minnesota, outside the submitted work.